Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 18/20 | 0.55 |
| ▸ | AKT2 | P31751 | 2/20 | 0.54 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.54 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.54 |
| ▸ | STK4 | Q13043 | 1/20 | 0.43 |
| ▸ | STK3 | Q13188 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4778647 | 0.88 | AKT1 (0.54) | AKT1AKT2RPS6KB1AKT3 | |
| SCHEMBL4776933 | 0.79 | AKT1 (0.57) | AKT1 | |
| SCHEMBL4726023 | 0.79 | AKT1 (0.57) | AKT1 | |
| SCHEMBL4780232 | 0.79 | AKT1 (0.57) | AKT1 | |
| SCHEMBL4795581 | 0.77 | AKT1 (0.71) | AKT1AKT2RPS6KB1AKT3 | |
| SCHEMBL4778852 | 0.76 | AKT1 (0.74) | AKT1AKT2RPS6KB1AKT3 | |
| SCHEMBL4778839 | 0.76 | AKT1 (0.74) | AKT1AKT2RPS6KB1AKT3 | |
| SCHEMBL4726079 | 0.75 | AKT1 (0.59) | AKT1AKT2RPS6KB1AKT3 | |
| SCHEMBL4781938 | 0.75 | AKT1 (0.59) | AKT1AKT2RPS6KB1AKT3 | |
| SCHEMBL4725153 | 0.75 | AKT1 (0.86) | AKT1AKT2RPS6KB1AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, CCND2, CCND1 | AKT1 752/4885AKT2 1098/4885RPS6KB1 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.